CA 102N

Drug Profile

CA 102N

Alternative Names: CA102N; HA-Nimesulide; Hyaluronic acid nimesulide-NH2 bioconjugate; Nim-HA Conjugate

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Holy Stone Healthcare
  • Class Antineoplastics; Drug conjugates
  • Mechanism of Action CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer; Solid tumours

Most Recent Events

  • 06 Aug 2018 Preclinical trials in Solid tumours in Taiwan (IV) (NCT03616574)
  • 06 Aug 2018 Holy Stone Healthcare plans a phase I trial for Solid tumours in November 2018 , (NCT03616574)
  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Colorectal cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top